Altimmune, Inc. Stock

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-16 EDT 5-day change 1st Jan Change
8.1 USD +2.53% Intraday chart for Altimmune, Inc. +17.39% -28.00%
Sales 2024 * 31.25M 42.74M Sales 2025 * 25M 34.18M Capitalization 574M 785M
Net income 2024 * -59M -80.68M Net income 2025 * -142M -194M EV / Sales 2024 * 16.3 x
Net cash position 2024 * 63.88M 87.35M Net cash position 2025 * 257M 351M EV / Sales 2025 * 12.7 x
P/E ratio 2024 *
-9.62 x
P/E ratio 2025 *
-6.43 x
Employees 59
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.64%
1 week+17.39%
Current month+21.80%
1 month+32.57%
3 months+7.71%
6 months-24.97%
Current year-28.00%
More quotes
1 week
7.41
Extreme 7.405
8.26
1 month
5.64
Extreme 5.64
8.49
Current year
5.64
Extreme 5.64
14.84
1 year
2.09
Extreme 2.09
14.84
3 years
2.09
Extreme 2.09
23.49
5 years
1.51
Extreme 1.51
35.10
10 years
1.51
Extreme 1.51
237.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 18-11-29
Director of Finance/CFO 36 20-09-30
Compliance Officer - 22-01-31
Members of the board TitleAgeSince
Chairman 76 10-03-31
Director/Board Member 72 04-07-31
Director/Board Member 56 03-08-31
More insiders
Date Price Change Volume
24-07-16 8.1 +2.53% 2,641,914
24-07-15 7.9 0.00% 2,027,967
24-07-12 7.9 +2.86% 2,526,748
24-07-11 7.68 +2.67% 4,497,289
24-07-10 7.48 +8.41% 4,030,311

Delayed Quote Nasdaq, July 16, 2024 at 04:00 pm

More quotes
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
8.1 USD
Average target price
20.57 USD
Spread / Average Target
+153.97%
Consensus